Elvia Cowan sold $557k of PCVX
SVP, FINANCE at Vaxcyte, Inc.. 11,623 shares at an average of $47.92, traded Dec 23, 2025, filed Dec 29, 2025.
Score components
- +15RoleOfficer
- +19Trade size$557k at market
- +10Share of holdings soldSold 44% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001960048-25-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 23, 2025 | SOpen-market sale Common Stock | -4,907 | $47.90 | $235k | 21,250 | Dec 29, 2025 |
| Dec 23, 2025 | SOpen-market sale Common Stock | -6,716 | $47.94 | $322k | 14,534 | Dec 29, 2025 |
| Dec 23, 2025 | GGift Common Stock | -1,000 | $0.00 | $0 | 13,534 | Dec 29, 2025 |
Related signals
Other insiders at Vaxcyte, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Vaxcyte, Inc. | Elvia Cowan SVP, Finance & CAO | $1.6M 19,000 shares | -41% | |
| 23Weak | Vaxcyte, Inc. | Jim Wassil EVP, Chief Scientific Ofc, COO | $1.6M 18,000 shares | -11% | |
| 4Weak | Vaxcyte, Inc. | Jim Wassil EVP, Chief Scientific Ofc, COO | $128k 2,250 shares | -2% | |
| 11Weak | Vaxcyte, Inc. | Jim Wassil EVP, Chief Scientific Ofc, COO | $164k 2,715 shares | -2% | |
| 0Weak | Vaxcyte, Inc. | Jim Wassil CHIEF OPERATING OFFICER | $212k 3,477 shares | -2% | |
| 5Weak | Vaxcyte, Inc. | Elvia Cowan SVP, Finance & CAO | $105k 1,892 shares | -6% | |
| 0Weak | Vaxcyte, Inc. | Elvia Cowan SVP, Finance & CAO | $146k 2,500 shares | -7% | |
| 50Moderate | Vaxcyte, Inc. | Harpreet S. Dhaliwal Chief Technical Ops Officer | $455k 9,743 shares | -29% | |
| 0Weak | Vaxcyte, Inc. | Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC | $354k 5,000 shares | -11% | |
| 15Weak | Vaxcyte, Inc. | Andrew Guggenhime PRESIDENT AND CFO | $671k 8,000 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.